⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Figure 6 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

Rosa A. van Amerongen Sander Tuit Dennis F.G. Remst Anne K. Wouters Sterre L. Siekman Renate S. Hagedoorn Dirk M. van der Steen Michel G.D. Kester Arnoud H. de Ru Geertje van der Horst Masashi Matsuda Fumihiko Ishikawa Peter A. van Veelen J.H. Frederik Falkenburg Mirjam H.M. Heemskerk

View at Publisher

Ask AI

Bookmark

Share

Key Points

T cell clones demonstrated a significant increase in ifn-γ production after coculture with specific Raji cells.
The study used various hla and klk transduced Raji cells to validate the t cell responses.
An effector:target ratio of 1:6 was maintained for coculture experiments to assess t cell activation.
Findings suggest kallikrein-related peptidase 4 is a viable target for enhancing prostate cancer treatment options.

Implication

T cell therapy increased ifn-γ in prostate cancer models, indicating it may effectively target kallikrein-related peptidase 4.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Amerongen et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d02a5 https://doi.org/10.1158/2326-6066.29759675

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
2Supplemental Figure 7 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
3Supplemental Figure 5 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
4Data from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
5Supplemental Figure 3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025

Supplemental Figure 2 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
Supplemental Figure 1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
Supplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025